Natalia P Rocha,Erin Furr-Stimming,Antonio L Teixeira
Natalia P Rocha
Evaluation of ctDNA-based ESR1 testing in breast cancer: results from the first external quality assessment scheme in China [0.03%]
中国首个基于ctDNA的ESR1检测外部质控评估方案在中国乳腺癌患者中的评价研究结果
Guigao Lin,Jing Li,Kuo Zhang
Guigao Lin
Background: Circulating tumor DNA (ctDNA) testing of plasma for ESR1 somatic variants is essential for guiding treatment decisions in hormone receptor-positive (HR + ) and HER2-negative (HER2-) advanced or metastatic brea...
Multi-omic profiling in breast cancer: utility for advancing diagnostics and clinical care [0.03%]
乳腺癌的多组学分析：用于促进诊断和临床治疗的技术
Emna El Gazzah,Scott Parker,Mariaelena Pierobon
Emna El Gazzah
Introduction: Breast cancer remains a major global health challenge. While advances in precision oncology have contributed to improvements in patient outcomes and provided a deeper understanding of the biological mechanis...
Anastasia Bougea
Anastasia Bougea
Introduction: In order to improve illnessidentification, monitoring, and patient outcomes, this special reportemphasizes the revolutionary potential of fluid and imaging biomarkers usingnew diagnostic technologies in Mult...
Extracellular vesicles as a source of biomarkers in hematological malignancies: looking toward clinical appilcations [0.03%]
血液系统恶性肿瘤中以细胞外囊泡作为生物标志物来源的临床应用研究
Claudia Ielo,Massimo Breccia
Claudia Ielo
Introduction: Extracellular vesicles are membranous particles released by cells in physiological and pathological conditions. Their cargo is heterogeneous since it includes different biomolecules such as nucleic acids and...
Marlies Gijs,Suzanne Hagan,Amalia Enríquez-de-Salamanca
Marlies Gijs
Evolution and future of cervical cancer screening: from cytology to primary HPV testing and the impact of vaccination [0.03%]
宫颈癌筛查的演变与未来：从细胞学检查到主要的人乳头瘤病毒检测及疫苗接种的影响
Mariam El-Zein,Eduardo L Franco
Mariam El-Zein
Introduction: Cervical cancer remains a significant global health challenge despite decades of progress in screening and prevention. Global cervical cancer screening practices vary substantially, with many countries still...
Homologous recombination deficiency: a reliable biomarker or a misleading indicator? [0.03%]
同源重组缺陷：可靠的生物标志物还是误导性的指标？
Hisamitsu Takaya,Shiro Takamatsu,Hidekatsu Nakai et al.
Hisamitsu Takaya et al.
Kristina R Dahlstrom,Erich M Sturgis,Karen S Anderson
Kristina R Dahlstrom
Mild behavioral impairment and neurodegeneration: time for a biomarker-based assessment [0.03%]
轻度行为障碍和神经退行性疾病：是时候进行生物标志物评估了
Maria Francesca Beatino,Lorenzo Lattanzi,Camilla Elefante et al.
Maria Francesca Beatino et al.